IXICO has unveiled research on a new artificial-intelligence tool designed to help radiologists spot tiny bleeds in the brain on MRI scans, a development that could be relevant to the next generation of Alzheimer’s drugs.
The company, which analyses brain scans to support drug trials and diagnostics in neurological disease, presented the work at a leading Alzheimer’s clinical-trials conference.
The tool targets cerebral microbleeds, small deposits of blood that show up as dark spots on an MRI. These matter because the latest anti-amyloid Alzheimer’s treatments can trigger such bleeds as a side effect, meaning patients must be monitored with repeated scans.
IXICO AI tool
Spotting these by eye is slow and can vary from one radiologist to another, so a reliable automated tool addresses a real-world problem and growing need.
IXICO said its two-stage system detected around 90% of the microbleeds in each scan, which it described as comparing favourably with other published results and performing consistently across different studies and imaging methods.
Robin Wolz, Chief Scientific Officer of IXICO, commented: “As new treatments for Alzheimer’s disease become increasingly available, the ability to monitor patient safety accurately and efficiently is more important than ever.”
“Detecting cerebral microbleeds is a critical part of this process but remains a time-consuming task that can be subject to variability between radiologists. Our research demonstrates the potential of AI to transform this process, delivering high levels of accuracy and consistency across different MRI techniques and patient populations.”
Investors should note this is a research and capability announcement, not a commercial contract, and it does not indicate short-term revenue generation.
